• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TESEVATINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • TESEVATINIB chembl:CHEMBL3544983 Antineoplastic

    Alternate Names:

    EXEL-7647
    XL-647
    KD-019
    KD019
    XL647
    TESEVATINIB
    KD-020

    Drug Info:

    Drug Class Kinase Inhibitors
    FDA Approval not approved
    Drug Class small molecule
    Drug Indications antineoplastic agent
    (3 More Sources)

    Publications:

    Pietanza et al., 2012, Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer., J Thorac Oncol
    Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.
    Trowe et al., 2008, EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation., Clin. Cancer Res.
  • TESEVATINIB   EPHB4

    Interaction Score: 11.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Ephrin type-B receptor 4 inhibitor
    Trial Name XL647

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

  • TESEVATINIB   PTK2B

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TESEVATINIB   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor
    Direct Interaction yes
    Evidence Type Actionable

    PMIDs:
    19718025 18413839


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

  • TESEVATINIB   EGFR

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor
    Direct Interaction yes
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    22722787


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

  • TESEVATINIB   FLT1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name XL647
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    MyCancerGenome TdgClinicalTrial

  • TESEVATINIB   FLT4

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name XL647
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    MyCancerGenome TdgClinicalTrial

  • TESEVATINIB   KDR

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name XL647
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial

  • MyCancerGenome: XL647

    • Version: 20-Jun-2017

    Alternate Names:
    XL647 Development Name
    KD019 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • TdgClinicalTrial: XL647

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: XL647

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Pietanza et al., 2012, Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer., J Thorac Oncol
    Trowe et al., 2008, EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation., Clin. Cancer Res.
    Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.

  • TALC: XL647

    • Version: 12-May-2016

    Alternate Names:
    XL647 Primary Drug Name
    XL647 Drug Synonym

    Drug Info:

    Publications:

  • TTD: KD019

    • Version: 2020.06.01

    Alternate Names:
    D06WRF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3544983

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3544983

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21